http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2695657-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_344090d436d27e041b7b9486cfdf560f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6827 |
| filingDate | 2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_673f1dd14569573158515157b3211d93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d8c93791223313b8b2552a7976f621c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e268c8c10c264fa75b1b719d78c2a5cd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45c63ad5ffb40cf1ab566896312b873c |
| publicationDate | 2019-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2695657-C1 |
| titleOfInvention | Method for predicting the efficacy of levomepromazine therapy for treating disorders accompanied by developing psychotic symptoms |
| abstract | FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to pharmacogenetics, clinical pharmacology, and can be used for dose selection levomepromazine in patients with psychotic symptoms. For this purpose, based on the results of genotyping using polymorphic markers of CYP2D6 genes, the resultant rate change is calculated biotransformation of levomepromazine (parameter P) by formula:,where: Wis the number of CYP2D6 gene polymorphisms (main pathway biotransformation of levomepromazine); A– change of speed biotransformation of levomepromazine, depending on the genotype for each polymorphic marker of the CYP2D6 gene. If change is defined as speed deviation biotransformation of levomepromazine by 50 % and higher, replacement of the drug is recommended. At change of speed defined as deceleration biotransformation of levomepromazine less than 50 % is recommended to reduce dose. If change is defined as speed acceleration biotransformation of levomepromazine more than by 50 %, dose increase is recommended.EFFECT: use of this method enables individual dose selection levomepromazine, determining degree of manifestation of deviation of its speed biotransformation depending on the genotype for each polymorphic marker of the CYP2D6 gene.1 cl, 1 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2722834-C1 |
| priorityDate | 2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.